Sponge-supported cultures of primary head and neck tumors for an optimized preclinical model
- PMID: 29861851
- PMCID: PMC5982753
- DOI: 10.18632/oncotarget.25244
Sponge-supported cultures of primary head and neck tumors for an optimized preclinical model
Abstract
Treatment of advanced head and neck cancer is associated with low survival, high toxicity and a widely divergent individual response. The sponge-gel-supported histoculture model was previously developed to serve as a preclinical model for predicting individual treatment responses. We aimed to optimize the sponge-gel-supported histoculture model and provide more insight in cell specific behaviour by evaluating the tumor and its microenvironment using immunohistochemistry. We collected fresh tumor biopsies from 72 untreated patients and cultured them for 7 days. Biopsies from 57 patients (79%) were successfully cultured and 1451 tumor fragments (95.4%) were evaluated. Fragments were scored for percentage of tumor, tumor viability and proliferation, EGF-receptor expression and presence of T-cells and macrophages. Median tumor percentage increased from 53% at day 0 to 80% at day 7. Viability and proliferation decreased after 7 days, from 90% to 30% and from 30% to 10%, respectively. Addition of EGF, folic acid and hydrocortisone can lead to improved viability and proliferation, however this was not systematically observed. No patient subgroup could be identified with higher culture success rates. Immune cells were still present at day 7, illustrating that the tumor microenvironment is sustained. EGF supplementation did not increase viability and proliferation in patients overexpressing EGF-Receptor.
Keywords: cell culture; head and neck cancer; primary tissue; sponge gel supported histoculture; squamous cell carcinoma.
Conflict of interest statement
CONFLICTS OF INTEREST The authors declare no potential conflicts of interest.
Figures
References
-
- Pulte D, Brenner H. Changes in survival in head and neck cancers in the late 20th and early 21st century: a period analysis. Oncologist. 2010;15:994–1001. https://doi.org/10.1634/theoncologist.2009-0289. - DOI - PMC - PubMed
-
- Epidemiology Surveillance End Results (SEER) Program. Oral Cavity and Pharynx Cancer.
-
- Epidemiology Surveillance End Results (SEER) Program. Larynx Cancer.
-
- Adelstein DJ, Li Y, Adams GL, Wagner H, Jr, Kish JA, Ensley JF, Schuller DE, Forastiere AA. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol. 2003;21:92–98. https://doi.org/10.1200/JCO.2003.01.008. - DOI - PubMed
-
- Pignon JP, le Maître A, Maillard E, Bourhis J, MACH-NC Collaborative Group Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009;92:4–14. https://doi.org/10.1016/j.radonc.2009.04.014. - DOI - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
